Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2011; 106(01): 172-174
DOI: 10.1160/TH11-02-0097
DOI: 10.1160/TH11-02-0097
Letters to the Editor
Durable responses to rituximab in acquired factor VIII deficiency
Authors
Further Information
Publication History
Received: 13 February 2011
Accepted after major revision: 25 March 2011
Publication Date:
24 November 2017 (online)
-
References
- 1 Huth-Kuhne A, Baudo F, Collins P. et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-575.
- 2 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112: 250-255.
- 3 Barnett B, Kruse-Jarres R, Leissinger CA. Current management of acquired factor VIII inhibitors. Curr Opin Hematol 2008; 15: 451-455.
- 4 Stockschlader M, Ruf L, Linderer A. et al. Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA. Thromb Haemost 2009; 101: 586-590.
- 5 Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141: 149-169.
- 6 Bresin E, Gastoldi S, Daina E. et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti- ADAMTS13 autoantibodies. Thromb Haemost 2009; 101: 233-238.
- 7 Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63: 47-52.
- 8 Karwal MW, Schlueter AJ, Zenk DW. et al. Treatment of acquired factor VIII deficiency with rituxi- mab. Blood. 2001 98. Abstract 533a.
- 9 Stasi R, Brunetti M, Stipa E. et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-4428.
- 10 Tay L, Duncan E, Singhal D. et al. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost 2009; 35: 769-777.
- 11 Nitta E, Izutsu K, Sato T. et al. A high incidence of late-onset neutropenia following rituximab-con- taining chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18: 364-369.
- 12 Tesfa D, Gelius T, Sander B. et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008; 25: 374-379.
- 13 Stamatopoulos K, Papadaki T, Pontikoglou C. et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituxi- mab-treated lymphoma patients with late-onset neutropenia. Leukemia 2008; 22: 1446-1449.
- 14 Ram R, Ben-Bassat I, Shpilberg O. et al. The late adverse events of rituximab therapy–rare but there!. Leuk Lymphoma 2009; 50: 1083-1095.
- 15 Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-1081.
- 16 Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-757.